Trials / Completed
CompletedNCT01056263
Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
Retrospective Observational Study Of Subjects With Cytokine-Refractory Metastatic Renal Cancer Treated With Axitinib (AG-013736) To Estimate 5-Yr Survival
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this observational study is to retrospectively collect current survival data for patients originally included in axitinib A4061012 \[NCT00076011\] study to estimate the 5-year survival rate in subjects with metastatic renal cancer cell treated with axitinib.
Detailed description
Subjects participating in this observational study originally participated in study A4061012 \[NCT00076011\], and may have also have participated in study A4061008 \[NCT00828919\]. Subjects participating in this observational study originally participated in study A4061012 \[NCT00076011\], and may have also have participated in study A4061008 \[NCT00828919\]. 5-year survival information to be updated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | axitinib: observational study | Non-interventional observational study |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2010-01-26
- Last updated
- 2012-04-20
- Results posted
- 2012-03-28
Locations
8 sites across 3 countries: United States, France, Germany
Source: ClinicalTrials.gov record NCT01056263. Inclusion in this directory is not an endorsement.